QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer

OBJECTIVE: A previous randomized phase II study showed that neoadjuvant nab-paclitaxel (nab-PTX) 100 mg/m(2)) was effective and well-tolerated in patients with HER2-negative early-stage breast cancer, compared with docetaxel (DTX). We evaluated patient outcomes in terms of the Functional Assessment...

全面介紹

Na minha lista:
書目詳細資料
發表在:Eur J Breast Health
Main Authors: Okuyama, Hiromi, Nakamura, Seigo, Akashi-Tanaka, Sadako, Sawada, Terumasa, Kuwayama, Takashi, Handa, Satoko, Kato, Yasuhisa
格式: Artigo
語言:Inglês
出版: Turkish Federation of Breast Diseases Associations 2018
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6170019/
https://ncbi.nlm.nih.gov/pubmed/30288492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/ejbh.2018.4174
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍